Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.62 |
| ▸ | AKT1 | P31749 | 2/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146231 | 0.88 | PIK3CA (1.00) | PIK3CACYP3A4PIK3CGAKT1DYRK1A | |
| SCHEMBL1621399 | 0.83 | PIK3CA (0.70) | PIK3CACYP3A4PIK3CGAKT1DYRK1A | |
| SCHEMBL1946980 | 0.81 | PIK3CD (0.76) | PIK3CACYP3A4PIK3CGAKT1DYRK1A | |
| SCHEMBL3146741 | 0.80 | PIK3CA (0.74) | PIK3CACYP3A4PIK3CGDYRK1APDPK1 | |
| SCHEMBL1620239 | 0.80 | PIK3CA (0.72) | PIK3CACYP3A4PIK3CGDYRK1APDPK1 | |
| SCHEMBL3140573 | 0.79 | PIK3CA (1.00) | PIK3CACYP3A4PIK3CGAKT1DYRK1A | |
| SCHEMBL20887557 | 0.79 | ABL1 (0.74) | PIK3CACYP3A4PIK3CGDYRK1A | |
| SCHEMBL3142719 | 0.78 | PIK3CA (1.00) | PIK3CACYP3A4PIK3CGDYRK1APDPK1 | |
| SCHEMBL3136731 | 0.78 | PIK3CA (0.78) | PIK3CACYP3A4PIK3CGDYRK1APDPK1 | |
| SCHEMBL1621000 | 0.78 | PIK3CG (0.69) | PIK3CACYP3A4PIK3CGAKT1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885CYP3A4 4192/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.